This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Chronic autoimmune active hepatitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Chronic autoimmune hepatitis is a chronic hepatitis of unknown origin that predominantly affects young and middle aged women. It is associated with HLA types A1, B8, DR3 and Dw3.

The cause of autoimmune hepatitis is unknown, but evidence implicates both genetic and environmental factors in its pathogenesis

  • an imbalance between effector and regulatory mechanisms leads to the breakdown of immune tolerance and the consequent development of an autoimmune attack
  • signalling pathways that have been implicated in the pathogenesis of autoimmune hepatitis involve the proinflammatory cytokines interferon-gamma, IL-12, tumour necrosis factor-alph, IL-6, and IL-23

There are reduced numbers of T-suppressor cells which results in the production of autoantibodies against hepatocyte surface antigens.

The condition may be referred to as lupoid hepatitis as a positive LE cell test occurs in about 15% of patients. However, the condition is distinct from classical systemic lupus erythematous.

The mainstay of treatment is non-specific immunosuppression, consisting of steroids with or without azathioprine

  • although most patients respond satisfactorily to steroid and thiopurine-based treatment regimens, up to 40% relapse and 10% undergo liver transplantation

Hepatocellular carcinoma develops in 1-9% of patients with autoimmune cirrhosis, with an annual incidence of 1.1-1.9% (2)

Reference:

  • Liberal R et al. Established and novel therapeutic options for autoimmune hepatitis. Lancet 2021; DOI: https://doi.org/10.1016/S2468-1253(20)30328-9
  • Muratori L, Lohse A W, Lenzi M. Diagnosis and management of autoimmune hepatitis BMJ 2023; 380 :e070201 doi:10.1136/bmj-2022-070201

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.